Logo Image
|Articles|December 10, 2015

Special Section Media, Communications & Social Media

Author(s)DIA

From enhancing the clinical trial recruitment process to providing a powerful tool for communicating drug safety, mobile technology and social media are quickly becoming part of the biopharmaceutical landscape. This Special Section of the December 2015 Global Forum explores the intersection of digital technology with the patient experience, and showcases forward-thinking applications of technology into the drug development process.

To read this article, click here.

Related to this article

View more
Pharmaceutical Executive Daily
Pharmaceutical Executive Daily: FDA Approves Tecentriq
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Read more
Naoki Okamura: Post-Patent Plan and Purpose
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
Read more